



Technical Assistance for Turkey in Horizon 2020 Phase-II EuropeAid/139098/IH/SER/TR

Turkey in Horizon 2020 II

Main Criteria and good practices for EIC Accelerator proposals Grigoris Chatzikostas









INDICATIVE PROPOSAL TEMPLATE



Ideation

- The pain point / problem to be solved
- The current solutions and their limitations
- Your value proposition
- Your targeted customers
- Your innovation
- · Your Unique Selling Point

Development

- The Objectives of your proposal
- The current status of your innovation
- The activities to develop your innovation, and their respective budget
- Your Team

Go to Market

- Your Targeted market
- Your Market size
- · Your Business model
- Your Go2Market strategy
- Your Financial projections
- · Your Financial needs
- Your IP assets and strategy
- · The impact on the market and beyond










IDEA AND SOLUTION:



Innovation in detail

What are the objectives

What are the challenges or problems – business, technological or societal (climate change, environment, gender dimension, etc.) - that you seek to address by bringing your innovation to market.












INNOVATION IN DETAIL



















OBJECTIVES



GO

The general objective of the project is to transform the existing Somatic Cell Counter prototype (TRL 6), based on flow cytometry coupled with fluorescence techniques, to a market-ready comprehensive solution (TRL 9) providing analysis, monitoring, and reporting on animal health and milk quality to dairy farmers and the dairy industry.

The starting point for the project is the prototype of a Somatic Cell Counter based on fluorescent flow cytometry, which has been tested in the lab and in a real world environment, with excellent performance in both cases. Based on this, two preproduction prototypes will be developed (the LASSI Somatic Cell Counter devices: a stand-alone device and a unit that will be integrated in Automatic Milking Systems). The devices will be bundled with an Internet of Things (IoT) platform (the LASSI platform) into the LASSI solution, which will provide services such as analysis, monitoring, and reporting on animal health and milk quality. The LASSI solution will provide dairy farmers with a Decision Support System (DSS) on animals' health, reports on animals' health history and milk quality logs, enabling them to rapidly diagnose mastitis by knowing the somatic cell count on individual cows, and save costs. The dairy industry will use the LASSI solution for determining remotely SCC on bulk milk quantities before loading it for transport, and for monitoring the quality of farms they cooperate with.

The specific objectives of the project are:

01

Advanced and specific development that will evolve the existing prototype to two separate pre-production prototypes:

- Stand-alone, portable, handheld SC Counter;
- Live measurement unit to be integrated into the milking system.

Based on the core device, **two pre-production prototypes** will be developed. The **handheld** device targets the issue of bulk milk quality control at the time of milk purchase from farmers. The **live measurement unit** will be developed to be integrated into Automatic Milking Systems (AMS), allowing continuous monitoring of SCC at the time of milking. The advanced development will include perfection of various system parts: lens, detector, rotational mechanism, and cleaning mechanism, in order to further improve the SC Counter's performance. Furthermore, it will include the design of the housing for both devices, and the implementation of the automatic sampling system for the automatic SC Counter.

Objective	Key Performance Indicators (KPIs)	Target values
Od: Brototuno	Time to design and integrate the industrial prototype of the handheld device	6 months
O1: Prototype	Time to design and integrate the industrial prototype of the automatic device	6 months
Development	Improvement of the accuracy of the device	±7%
O2: Solution	User interfaces meet usability needs of the users	85%
Development	Acceptance of the proposed services by users	90%
	No. of full systems for milk quality control installed	1
O3: Validation	Number of full systems for cow health control installed	1
	Success rate of the performed system validation tests	90%
	No of devices assemble to a few teating (benedicted)	40









THE PROBLEM



QF4 Please tell me to what extent you are worried or not about the following issues.

Answer: Total 'Worried'

"Higher levels of Worry"

	"Higher levels of Worry"											
	Pesticide residues in fruit, vegetables or cereals			anti	Residues like antibiotics or hormones in meat		Pollutants like mercury in fish and dioxins in pork			Cloning animals for food products		
7		EU27	72%		EU27	70%		EU27	69%		EU27	65%
(EL	91%	(CY	92%	(CY	85%	(EL	76%
(3	CY	90%		EL	87%	\mathbf{O}	IT	83%	\mathbf{O}	IT	75%
		LT	88%		LT	84%		LT	82%		LU	75%
(SE	59%	4	UK	53%		NL	57%		EE	48%
(NL	53%		SE	50%		UK	51%	\mathbf{O}	ΙE	48%
•	4 P	UK	53%	(FI	48%		SE	46%		MT	48%

Figure 1: Pesticide residues - The major food-related concern of European citizens (Source: Eurobarometer 354)










INNOVATIVENESS



How is your innovation better or significantly different than other existing alternatives?

Why is the timing right for your innovation?











COMPARISON TO EXISTING ALTERNATIVES



Table 6: Technical characteristics of the competitive solutions

	Test tape method (Porta SCC)	California Mastitis Test (CMT) (Ekomilk SCAN)	Automatic counting based on image cytometry technology (DeLaval Cell	Automatic counting based on flow cytometry technology (Fossomatic™ FC)	LASSI
			Counter)	(
Measuring speed	45 min for regular, and 5 min for quick test	4 min/measurement	·	200, 300, 400, 500 or 600 samples/hr	100,000 to 1,000,000 somatic cells per ml in laboratory conditions in less than 60 seconds
Measuring range	100.000 - 3.000.000 somatic cells/ml	90.000 – 1.500.000	10.000 to 4.000.000 somatic cells/ml	0 – 10 mill cells/ml	100,000 to 1,000,000 somatic cells per ml
Sample intake	2 ml	10 ml	Approx 60 µl in the cassette / Measuring volume: Approx 1 µl	2.5 ml (programmable 2.0 – 5.0 ml)	2 ml
Required sample temperature	0 - 8°C	15° - 30°C	10° - 40°C	30 - 42 °C	15 – 25 °C
Sample types	Bulk tank or individual sample	Bulk tank or individual sample		Cow's, goat's, sheep's milk and other	Any type of milk, bulk or individual animal.
Dimensions (HxWxD)		20 x 26 x 29 cm	23,5 x 23,6 x 24,9 cm	63 x 85 x 68 cm	10 x 10 x 5 cm
Weight	Digital reader ~ 200 g Tapes – N/A	< 4,5 kg	4.1 kg	100 kg	<1kg
Power supply	N/A - manual	AC Power Supply voltage 220V +10%/- 15% / DC Power Supply voltage 12V to 14,2V		100 - 240 VAC, 50/60 Hz	12V DC power supply
Portable	Yes - handheld	Yes - tabletop	Yes – tabletop	No	Yes - handheld
Customers	Dairy farmers & milk industry companies	Dairy farmers & milk industry companies	Small milk laboratories and dairy farmers	Laboratories	Dairy farmers & milk industry companies
User level	Non-expert	Non-expert	Non-expert	Expert	Non-expert
Price range	<100 €	1 – 3 k €	<10 k €	> 10 k €	250 €









TIMING: HYPE CYCLES



- Innovation Trigger: A potential technology breakthrough kicks things off. Early proof-of-concept stories and media interest trigger significant publicity. Often no usable products exist and commercial viability is unproven.
- Peak of Inflated Expectations: Early publicity produces a number of success stories often accompanied by scores of failures. Some companies take action; many do not.
- Trough of Disillusionment: Interest wanes as experiments and implementations fail to deliver. Producers of the technology shake out or fail. Investments continue only if the surviving providers improve their products to the satisfaction of early adopters.
- Slope of Enlightenment: More instances of how the technology can benefit the enterprise start to crystallize and become more widely understood. Second- and third-generation products appear from technology providers. More enterprises fund pilots; conservative companies remain cautious.
- Plateau of Productivity: Mainstream adoption starts to take off. Criteria for assessing provider viability are more clearly defined. The technology's broad market applicability and relevance are clearly paying off.










TIMING: HYPE CYCLES














STAGE OF DEVELOPMENT:



Current stage of development) Technology Readiness Levels),

Activities and results achieved so far.

Next steps planned to take this innovation to the market?











CURRENT STAGE OF DEVELOPMENT



Statu	S		
Initial set of services	Irrigation optimization (irrigNET) Pest control (trapNET)	13 supported crops	
ready:	Crop disease prediction (alertNET)	Prediction of 12 diseases	
	Image based analysis of fields (fieldNET)	Monitoring of 2 types of pests	
	Machinery and asset control (fleetNET)	Pilot deployments done over the last	
	Asset management in orchards (boxNET)	two years Onboarding customers in progress	
	Farm activities log book (activityBOOK)		







GENERAL SAND RESULTS ACHIEVED SO FAR AND NEXT STEPS IN THE PROPERTY OF THE PRO




Figure 9: Project stages











FEASIBILITY





- Technological
- Practical
- Economic

Product Development Process



Customer Development Process













RISKS




The EIC Accelerator supports high-risk, high-potential small and medium-sized enterprises and innovators to help them develop and bring onto the market new innovative products, services and business models that could drive economic growth.

BUSINESS RISKS (Excellence)

VS

PROJECT RISKS (Implementation)














MARKET AND CUSTOMERS



- Market assessment (inc. conditions and growth rate)
- Potential customers
- Unique Selling Points
- Differentiators















POTENTIAL CUSTOMERS



MARKET SIZE

	Nu		er of farm holdi	ngs	Utilised	agricultural are	ea <u>in ha</u>	Star	ndard output (EUR)	Livestock un	its on holdings v	vith livestock
	Avg Farm Size	All Farms	Very small & Small Farms	Large Farms	All Farms	Very small & Small Farms	Large Farms	All Farms	Very small & Small Farms	Large Farms	All Farms	Very small & Small Farms	Large Farms
Spain	24,1	965.000	758.000	52.000	23.300.000	3.559.000	12.939.000	35.979.000	16.129.000	9.049.000	14.502.000	7.409.000	3.051.000
Ireland	35,5	140.000	60.000	5.000	4.959.000	658.000	1.152.000	5.013.000	652.000	887.000	5.929.000	899.000	795.000
Serbia	4,5	650.000						5.300.000			1.800.000		
France	58,7	472.000	202.000	98.000	27.739.000	1.164.000	17.170.000	56.914.000	10.977.000	24.481.000	21.871.000	2.787.000	9.741.000
Germany	58.6	285.000	128.000	35.000	16.700.000	1.257.000	9.514.000	46.252.000	7.301.000	20.440.000	18.407.000	3.938.000	6.802.000
Italy	12	1.010.000	880.000	15.000	12.099.000	4.171.000	3.259.000	43.794.000	20.066.000	7.608.000	9.374.000	3.340.000	1.991.000
The Netherlands	27,4	67.000	38.000	2.000	1.848.000	255.000	369.000	20.498.000	9.216.000	2.066.000	6.602.000	2.983.000	446.000
EU-28	16	10.841.000	9.353.000	337.000	174.614.000	32.276.000	90.966.000	331.105.000	107.887.000	110.792.000	130.174.000	40.046.000	40.609.000
Note: Very small	and small	farms are def	fined by a utlise	d agricultu	ıral area <20 l	na; large farms	are defined b	oy a utilized a	gricultural are	a with over 10	00ha		

Figure 5 Market Size Statistics

MARKET SEGMENTATION

Customer Segment	Solution	Solution Functionality		Pricing Policy		
CS-A1: small dairy farms	Stand-alone device & IT Platform	Test Milk Quality Instantly & Remotely	Device € 250	Platform € 100 Yearly Subscription		
CS-A2: Medium and large- sized farms	Stand-alone device & IT Platform	Test Milk Quality Instantly & Device € Remotely 250		Platform € 100 Yearly Subscription		
CS-A2: Medium and large- sized farms	Live measurement Unit & IT Platform	Integrate to milking system	Device € 350	Platform € 150 Yearly Subscription		
CS-B: Dairy industry	Stand-alone device & IT Platform	Test Milk Quality Instantly & Remotely	Device € 250	Platform € 1.500 Yearly Subscription		
CS-C: Milking Systems Industry (AMS)	Live measurement Unit & IT Platform	Integrate to their milking systems and resale	Device € 300	Platform € 100 Yearly Subscription		








"A unique selling proposition or point (USP) refers to the unique benefit exhibited by a company, service, product or brand that enables it to stand out from competitors. The unique selling proposition must be a feature that highlights product benefits that are meaningful to consumers.

Unique value proposition of LASSI:

LASSI combines the advantages of the state-of-the-art solutions into a disruptive innovative solution. **High accuracy** and **high speed** are accomplished by using fluorescent flow cytometry, the fastest and alongside direct microscopy, the most accurate method for determining the SCC. **Ease-of-use** is achieved by automation of the sample preparation and cleaning processes. **Low price** is achieved with innovative design and use of readily available components to create a novel device. Additionally, LASSI handheld SC counter is **portable** due to its small size and it is the first handheld SC counter based on flow cytometry.

Table 4: Overall characteristics of existing solutions

	Accuracy	Ease-of-use	Speed	Price	Portability
Test tape method	Low	Yes	Slow	Low	Yes
California Mastitis Test (CMT)	Low	Yes	Slow	High	Yes
Automatic counting based on image cytometry technology	High	Moderate	Fast	High	Yes
Automatic counting based on flow cytometry technology	High	No	Fast	High	No
LASSI	High	Yes	Fast	Low	Yes











COMMERCIALIZATION STRATEGY



- Strategy for commercialization
- Regulatory approvals/compliance needed
- Time to market/deployment
- Revenue model










COMMERCIALIZATION STRATEGY














REVENUE MODEL



A revenue model is a framework for generating revenues. It identifies which **revenue source** to pursue, what **value** to offer, how to **price** the value, and **who pays** for the value.



SALES	Year 1
CS-A1: Small farmers	
P1: Stand Alone Device & IT Platform (Sales)	180.000,00€
Number of new customers	300
Number of stand alone devices sold	600
Number of IT Platform Subscriptions	300
CS-A2: Medium and large-sized farms	
P1: Stand Alone Device & IT Platform	337.500,00€
Number of new customers	250
Number of stand alone devices sold	1.250
Number of IT Platform Subscriptions	250










EXTERNAL STRATEGIC PARTNERS



- Key partners required to develop and commercialise your innovation,
- What their roles/competences are
- To what extent they are already committed and incentivized











LETTERS OF INTENT



From relevant organizations
Custom (explain their interest in the letter)
Singed by decision makers
Scanned copy in Annex



Generali Osiguranje Srbija a.d Vladimira Popovića 8 11070 Beograd / Srbija T +381.11.222.0.555 F +381.11.711.43.81 kontakt@generali.rs

INOSENS.rs

26th February 2018

To Whom It May Concern:

As a Head of Department for insurance in Agriculture at Generali Osiguranje Srbija ADO, I am greatly interested in the activities undertaken by the BEACON project submitted by KARAVIAS, in response to the topic DT-SPACE-01-EO-2018-2020 —"Digitising and transforming European industry and services (DT)" of the Horizon 2020 Programme.

The proposal aims to deliver agricultural insurance services into a commercial service package that will enable insurance companies to alleviate the effect of weather uncertainty when estimating risk for Agricultural Insurance products, reduce the number of on-site visits for claim verification, reduce operational and administrative costs for monitoring of insured indexes and contract handling, and design more accurate and personalised contracts by using Earth Observation data and weather intelligence, matching them with Blockchain technology and Smart Contracts applications.

As we are interested to supplement our services with advanced insurance solutions, BEACON will give us the opportunity to use current, historical and forecast EO and meteorological data, so that we enhance the estimation of the undertaken risks and crop losses and design the premiums with greater accuracy.

For the reasons above I am writing to confirm our interest in collaborating with BEACON, helping to define requirements, test and validate the proposed solution as well as being able to make use of the envisaged solution.



Akcionansko druživo za osiguranje GENERALJ OSIGURANJE SRBIJA, Beograd, Vladimira Popovića i Matični broj 17198319 PIB 100001175

Društvo pripada Generali grupi upisanoj u Registar osiguravajućih grupa Italije koji vodi IVAS











INTELLECTUAL PROPERTY



- Specify your Intellectual Property Rights in relation to your innovation.
- What are the key assumptions
- What measures are needed to ensure freedom to operate (e.g. IP, etc.)?

Broader area	Patent	Description			
	US2015253302 (A1)	Based on microflow cytometry and impedance measurement. Static microchannels suffer from clogging and fabrication tolerances. Market potential questionable.			
	US2014139834 (A1)	Approximation based on two-variable equation. Not very precise.			
SCC detectors	CN102819765 (A)	Image cytometry based counter.			
SCC detectors	US2012310541 (A1)	Apparatus for dielectric spectroscopy of milk. Not ideal for determining SSC.			
CN1789983 (A)		Colorimetric method of detecting somatic cells in liquid phase. Cumbersome sample preparation.			
	US6307362 (B1)	Somatic cell analyser based on detection of sodium ions. Unreliable technique.			
	NZ608803 (A)	A method for discrimination of cells, no device is discussed.			
	NZ580123 (A)	An indirect method, based on detection of oxygen levels in milk.			
Methods for	JP2010230363	A method based on active oxygen detection. Market take-up unlikely.			
detection	WO2010079469 (A1)	Method based on CMT. There are commercially available solutions using this method. Accuracy is not very high.			
	WO2005018414 (A2)	A method based on detection of nucleic acid in milk.			
	US2008057596 (A1)	Colorimetric method of detecting somatic cells, similar to PortaSCC, but in liquid phase.			










SCALE UP POTENTIAL



 How you intend to scale up your innovation, including the potential to develop new markets

• What the impact of the innovation on the growth of the company will be.












SCALE UP POTENTIAL - NEW MARKETS













IMPACT ON GROWTH OF THE COMPANY





	Current Situation	After KATANA		
Market Share	<1% of Serbian market	3% of Serbian market 1st marketplace for PA solutions in Europe		
Customer base	Private companies: Delta Agrar, Plantaže, Victoria Group and MK Group Public sector organizations: Regional Government of Vojvodina (Dept. Of Agriculture) and the Waters of Vojvodina organization	customers)		
Local Business Portfolio	4 paying customers, all in Serbia	+10 paying customers in Serbia		
International Business Portfolio	None	500 paying customers in Europe		
No. of Employees	3	12		
Business Activities	ICT Technologies for Agriculture	ICT Technologies for Agriculture		
Potential Turnover Increase (%) and (k€)	-	+150% +750k EUR		









KEY PERFORMANCE INDICATORS



KPIs for the expected outcomes and the related success criteria for the innovation (i.e. the technological, practical, economic, market)

Current values and the target values at specified dates (breakeven point, etc.).

Key Performance Indicators (KPIs)	Target values
Project Success Indicators	
% of outage due to changes (planned unavailability)	<3%
% of actual uptime	>97%
AgI Process cycle-time decrease (%)	60%
BEACON market readiness	
% of automation workflow achieved on AgI company level	90%
% of automation workflow achieved on AgI supply chain level	80%









BROADER IMPACT



- Societal,
- Economic,
- Environmental
- Climate impacts

be if your innovation if successfully commercialised?

Under this framework MOZART contributes in high priority issues in the EU Environmental Agenda related to agriculture, as reflected in various legislative documents such as the Framework Directive on the Sustainable Use of Pesticides (2009/128/EC), which demands all Member States to adopt National Action Plans setting quantitative objectives, targets, measures and timetables to reduce risks and impacts of pesticide use on human health and the environment. Other relative EU legislative and/or institutional initiatives in the field include Directive (2009/127/EC) with regard to machinery for pesticide application (for the first time, the Directive will also cover certain environmental protection requirements) and of course the Common Agricultural Policy (CAP) and more specifically the cross compliance scheme that couples subsidies to farmers with environmental criteria.










TEAM AND CAPABILITIES



- Team
- Different roles and commitment
- Achievements/experience (strategic, technical and commercial) in relation to your innovation
- Role of the company's owner(s) if not part of the team.
- Shareholding and stock options of team members (including owners).
- Strengths and weaknesses of the team
- Plans to acquire currently missing competencies
- Incentives for team members











ROLES AND COMMITMENT



Team Member (Name and Surname)	Position	Department	Function/ key competencies	Commitment (from 1-100% where 100% is full time, i.e. no other commitment outside of the company)
	CEO			?
	СТО			
	COO			
	СМО			
	Other?			

THE WALL STREET JOURNAL.

Subscribe | Sign In

Home World U.S. Politics Economy **Business** Tech Markets Opinion Life & Arts Real Estate WSJ. Magazine Q

BUSINESS | MANAGEMENT | MANAGEMENT & CAREERS

Who Wants to Be a Ninja? Job Titles Get a Rebranding

Companies hire for 'data wranglers,' 'growth hackers' in the race for talent









ACHIEVEMENTS AND EXPERIENCE



Strategic (CEO)
Technical (CTO)
Commercial (CMO)
...In relation to your innovation



Download Photo

Website

Ben Horowitz is a cofounder and general partner at the venture capital firm Andreessen Horowitz. He is the author of the *New York Times* bestsellers, *The Hard Thing About Hard Things* and *What You Do Is Who You Are*. He also created the a16z Cultural Leadership Fund to connect the greatest cultural leaders to the best new technology companies, and enable more young African Americans to enter the technology industry.

Prior to a16z, Ben was cofounder and CEO of Opsware (formerly Loudcloud), which was acquired by Hewlett-Packard for \$1.6 billion in 2007, and was appointed vice president and general manager of Business Technology Optimization for Software at HP. Earlier, he was vice president and general manager of America Online's E-commerce Platform division, where he oversaw development of the company's flagship Shop@AOL service. Previously, Ben ran

several product divisions at Netscape Communications. He also served as vice president of Netscape's widely acclaimed Directory and Security product line. Before joining Netscape in July 1995, he held various senior product marketing positions at Lotus Development Corporation.

Ben has an MS in Computer Science from UCLA and a BA in Computer Science from Columbia University.









STOCK OPTIONS OF TEAM MEMBERS



An employee stock ownership plan (ESOP) is an employee benefit plan that gives workers ownership interest in the company. Startups often use ESOPs as a corporate-finance strategy and to incentivize employees, align their interests with those of their shareholders and compete against large companies in attracting talent.

TYPICAL PRE-FINANCING EQUITY

Position	Range %
Founding CEO	30-60%
Active Founding Scientist	20-40%
Passive Founding Scientist	1-5%
University Founding Equity	2-20%
Professional CEO (Series ~A/B)	5-10%
C-Level	2-5%
Lead Engineer / Scientist	1-2%
Engineer (5+ years)	0.66-1.25%
Engineer (Junior)	0.2-0.66%
Ind. Board Member/Advisor	1%

- Titles range from CTO, CEO, Chief Scientist
- Many are part time, but spend at least 30% of their time at the startup
- · Get 20% median and 25% mean initial equity
- The most highly compensated are founding scientist CEOs, which is rare
- Active Founding Scientist are more typical in tech companies (less common in biotech)
- Titles range from nothing, Advisor, Scientific Advisory Board to Chief Scientist
- Spending very little time day to day at the startup and some are not in touch with their companies at all
- · Get less than 5% initial equity









CREDIBLE AND REALISTIC ASSESMENT

STRENGHTS	WEAKNESSES
Technical know - how	Lack of sales/ marketing skills
Long-term previous collaboration	Limited contacts in Europe
Commitment	Lack of hierarchy
••••	

AMBITIOUS PLANS











INCENTIVES




FINANCIAL INCENTIVES

- Salaries
- Stock options
- Bonus (based on targets)
- Other?

NON-FINANCIAL INCENTIVES

- Flexible working hours
- Training/travelling
- Team-building activities
- Company car
- Working environment
- Working for a purpose
- Other?











FINANCIAL NEEDS



- Estimation of the total financial resources
- Required timing of financial needs to develop your innovation and to reach the break-even point

FINANCIAL TABLES

- Simplified financial information on revenues, expenditures, cash flow and balance sheet;
- Company up-to-date financial data relating to cash and debt;
- Summary information about company financial history;
- Company ownership and capital structure (Blended applicants only);
- Information about current financing round.









PROJECT RISKS



Risk Description	WP(s)	Proposed risk-mitigation measures(Initial Contingency Plan)		
Technical Risks				
Not all requirements captured	2	(R): Not all requirements were recorded and analyzed. (M) : Regular review and validation of outputs and interaction with stakeholders and expert group.		
LIT-MS mass range	3	(R): Molecular weights of VOCs higher than the mass range that the LIT-MS can detect, which will make it unable to be detected in the open field. (M): Alterations to the electronics to increase the mass range of the instrument.		
LIT-MS sensitivity	3	(R): Field detection encounters low concentration levels require increased sensitivity. (M): Examine different types of inlets to increase sensitivity.		
LIT-MS resolution	3	(R): In on-site measurements there are compounds that interact among them and give close peaks. (M): These components need to be properly distinguished. High resolving power for analyzes of interest is a solution for that risk.		

Description of risk	WP(s) involved	Proposed risk-mitigation measures
Development risks arising from not	WP2	The design of the system and the product specifications will
achieving the set objectives for the LASSI		be enhanced with the involvement of target users early in
hardware and software solution		the project implementation.
Incomplete understanding of customer use	WP2	Create a tight feedback loop between the user responses
cases which can cause a misfit of the		and the technical activities. Run case studies in parallel to
solution to the users' need		the technical activities to allow for continuous assessment
		of the results.
Customer take-up below expectations	WP4, WP6	Intensify promotional efforts. Interview customers and
		analyse their experience and reasons for slow take-up.
		Increase viral distribution incentives.










PITCH DECK



Total duration 10 mins:

Company Purpose
Problem & Solution
Value Proposition
Market Opportunity & Risks
Competition
Business Model
Commercialisation & Marketing
Strategy
Financial Projections Team
Conclusion



In Second stage of the evaluation, the pitch document cannot be changed anymore

One slide for each heading















